Session Synopsis: Advanced diagnostics plays a critical role in precision medicine, insuring that patients receive the most appropriate treatment. However, regulatory uncertainty as well as difficulties with reimbursement difficulty, create a challenging funding environment for innovation. This session’s discussion will focus on where the diagnostics industry is today as well as its outlook for the future.
Session Chair Profile
President & Chief Executive Officer, Biocept
Mr. Nall has over 25 years of healthcare sales and marketing experience, most recently serving at Clarient Diagnostic Services, Inc. in positions of increasing responsibility from 2002 through 2013. While at Clarient, Mr. Nall was also responsible for leading the team assimilating Clarient into GE Healthcare after being acquired in 2010. From 1988 until joining Clarient, Mr. Nall served in the diagnostic and medical device industries in various commercial leadership roles for companies including Impath, American Cyanamid, Maquet Surgical, Strato Medical, Horizon Medical Products and Columbia Vital Systems. Mr. Nall received a Bachelor of Science degree in Business Administration from Central Missouri State University (now known as the University of Central Missouri).
M.D., Chief Clinical Officer, ADVI
Louis Jacques, M.D. is Chief Clinical Officer and a Senior Vice President at ADVI, a health care advisory services firm. He also serves on several institutional boards and advisory panels. Before joining ADVI in 2014, Dr. Jacques was the Director of the Coverage and Analysis Group (CAG) in the Centers for Medicare & Medicaid Services (CMS) from 2009 – 2014, where he managed Medicare fee for service coverage policy development on technologies as diverse as molecular diagnostic testing, implanted cardiac devices, advanced imaging, chemotherapeutics, wound care, and screening and preventive services. From 2004 – 2009 he was a division director within CAG, focusing on Part B drugs and diagnostic tests. Before joining CMS in 2003, was Associate Dean for Curriculum at Georgetown University School of Medicine; where he saw patients at the Lombardi Cancer Center in his practice of hospice and palliative medicine.
Chairman of the Board, President and Chief Executive Officer of Veracyte
Bonnie Anderson is Chairman of the Board, President and Chief Executive Officer of Veracyte, a leading genomic diagnostics company that improves the lives of patients by reducing diagnostic uncertainty in healthcare, enabling patients to get diagnosed sooner and avoid risky, costly surgery that is often unnecessary. Ms. Anderson cofounded Veracyte in 2008, took the company public in 2013 and has spearheaded Veracyte’s commercialization successes to date. Her career spans over 30 years in regulated diagnostics and life science markets. Prior to Veracyte, Ms. Anderson provided strategic consulting services to venture capital firms and early-stage businesses following 18 years in leadership positions at Beckman Coulter. She serves on the board of Castle Biosciences and on the steering committee for the Coalition for 21st Century Medicine and is a trustee emeritus of the Keck Graduate Institute of Applied Life Sciences. Ms. Anderson has received numerous awards in her career, including being named to Fast Company’s “100 Most Creative People in Business” list (2015) and to the San Francisco Business Times’ list of the “Bay Area’s Most Admired CEOs” (2014).